Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">C-X-C Motif Chemokine 13 (CXCL13) Is a Prognostic Biomarker of Idiopathic Pulmonary Fibrosis</title><author><name sortKey="Vuga, Louis J" sort="Vuga, Louis J" uniqKey="Vuga L" first="Louis J." last="Vuga">Louis J. Vuga</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Tedrow, John R" sort="Tedrow, John R" uniqKey="Tedrow J" first="John R." last="Tedrow">John R. Tedrow</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Pandit, Kusum V" sort="Pandit, Kusum V" uniqKey="Pandit K" first="Kusum V." last="Pandit">Kusum V. Pandit</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Tan, Jiangning" sort="Tan, Jiangning" uniqKey="Tan J" first="Jiangning" last="Tan">Jiangning Tan</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Kass, Daniel J" sort="Kass, Daniel J" uniqKey="Kass D" first="Daniel J." last="Kass">Daniel J. Kass</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Xue, Jianmin" sort="Xue, Jianmin" uniqKey="Xue J" first="Jianmin" last="Xue">Jianmin Xue</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Chandra, Divay" sort="Chandra, Divay" uniqKey="Chandra D" first="Divay" last="Chandra">Divay Chandra</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Leader, Joseph K" sort="Leader, Joseph K" uniqKey="Leader J" first="Joseph K." last="Leader">Joseph K. Leader</name><affiliation><nlm:aff id="aff2"></nlm:aff></affiliation></author><author><name sortKey="Gibson, Kevin F" sort="Gibson, Kevin F" uniqKey="Gibson K" first="Kevin F." last="Gibson">Kevin F. Gibson</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Kaminski, Naftali" sort="Kaminski, Naftali" uniqKey="Kaminski N" first="Naftali" last="Kaminski">Naftali Kaminski</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Sciurba, Frank C" sort="Sciurba, Frank C" uniqKey="Sciurba F" first="Frank C." last="Sciurba">Frank C. Sciurba</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Duncan, Steven R" sort="Duncan, Steven R" uniqKey="Duncan S" first="Steven R." last="Duncan">Steven R. Duncan</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24628285</idno><idno type="pmc">4098096</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098096</idno><idno type="RBID">PMC:4098096</idno><idno type="doi">10.1164/rccm.201309-1592OC</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000865</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000865</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">C-X-C Motif Chemokine 13 (CXCL13) Is a Prognostic Biomarker of Idiopathic Pulmonary Fibrosis</title><author><name sortKey="Vuga, Louis J" sort="Vuga, Louis J" uniqKey="Vuga L" first="Louis J." last="Vuga">Louis J. Vuga</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Tedrow, John R" sort="Tedrow, John R" uniqKey="Tedrow J" first="John R." last="Tedrow">John R. Tedrow</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Pandit, Kusum V" sort="Pandit, Kusum V" uniqKey="Pandit K" first="Kusum V." last="Pandit">Kusum V. Pandit</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Tan, Jiangning" sort="Tan, Jiangning" uniqKey="Tan J" first="Jiangning" last="Tan">Jiangning Tan</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Kass, Daniel J" sort="Kass, Daniel J" uniqKey="Kass D" first="Daniel J." last="Kass">Daniel J. Kass</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Xue, Jianmin" sort="Xue, Jianmin" uniqKey="Xue J" first="Jianmin" last="Xue">Jianmin Xue</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Chandra, Divay" sort="Chandra, Divay" uniqKey="Chandra D" first="Divay" last="Chandra">Divay Chandra</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Leader, Joseph K" sort="Leader, Joseph K" uniqKey="Leader J" first="Joseph K." last="Leader">Joseph K. Leader</name><affiliation><nlm:aff id="aff2"></nlm:aff></affiliation></author><author><name sortKey="Gibson, Kevin F" sort="Gibson, Kevin F" uniqKey="Gibson K" first="Kevin F." last="Gibson">Kevin F. Gibson</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Kaminski, Naftali" sort="Kaminski, Naftali" uniqKey="Kaminski N" first="Naftali" last="Kaminski">Naftali Kaminski</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Sciurba, Frank C" sort="Sciurba, Frank C" uniqKey="Sciurba F" first="Frank C." last="Sciurba">Frank C. Sciurba</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author><author><name sortKey="Duncan, Steven R" sort="Duncan, Steven R" uniqKey="Duncan S" first="Steven R." last="Duncan">Steven R. Duncan</name><affiliation><nlm:aff id="aff1"></nlm:aff></affiliation></author></analytic><series><title level="j">American Journal of Respiratory and Critical Care Medicine</title><idno type="ISSN">1073-449X</idno><idno type="eISSN">1535-4970</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><bold>Rationale:</bold> C-X-C motif chemokine 13 (CXCL13) mediates B-cell trafficking and is increased, proportionately to disease activity, in many antibody-mediated syndromes. Dysregulated B cells have recently been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis.</p><p><bold>Objectives:</bold> To determine if CXCL13 is associated with IPF progression.</p><p><bold>Methods:</bold> CXCL13 was measured in lungs by DNA microarray and immunohistochemistry, and in plasma by ELISA.</p><p><bold>Measurements and Main Results:</bold> CXCL13 mRNA was threefold and eightfold greater in IPF lungs (n = 92) compared with chronic obstructive pulmonary disease (COPD) (n = 191) and normal (n = 108) specimens, respectively (<italic>P</italic> < 0.0001). IPF lungs also showed increased CXCL13 staining. Plasma CXCL13 concentrations (pg/ml) were greater in 95 patients with IPF (94 ± 8) than in 128 subjects with COPD (53 ± 9) and 57 normal subjects (35 ± 3) (<italic>P</italic> < 0.0001). Circulating CXCL13 levels were highest in patients with IPF with pulmonary artery hypertension (<italic>P</italic> = 0.01) or acute exacerbations (<italic>P</italic> = 0.002). Six-month survival of patients with IPF in the highest quartile of plasma CXCL13 was 65 ± 10% versus 93 ± 10% in the others (hazard ratio, 5.5; 95% confidence interval, 1.8–16.9; <italic>P</italic> = 0.0008). CXCL13 increases by more than 50% in IPF serial assays, irrespective of initial values, also presaged respiratory failure (hazard ratio, 7.2; 95% confidence interval, 1.3–40.0; <italic>P</italic> = 0.008). In contrast, CXCL13 clinical associations in subjects with COPD were limited to modest correlations with FEV<sub>1</sub> (<italic>P</italic> = 0.05) and progression of radiographic emphysema (<italic>P</italic> = 0.05).</p><p><bold>Conclusions:</bold> CXCL13 is increased and is a prognostic biomarker in patients with IPF, and more so than in patients with COPD. This contrast indicates CXCL13 overexpressions are intrinsic to IPF, rather than an epiphenomenon of lung injury. The present data implicate CXCL13 and B cells in IPF pathogenesis, and support considerations for trials of specific B-cell–targeted therapies in patients with this intractable disease.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Respir Crit Care Med</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Respir. Crit. Care Med</journal-id><journal-id journal-id-type="publisher-id">ajrccm</journal-id><journal-title-group><journal-title>American Journal of Respiratory and Critical Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">1073-449X</issn><issn pub-type="epub">1535-4970</issn><publisher><publisher-name>American Thoracic Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24628285</article-id><article-id pub-id-type="pmc">4098096</article-id><article-id pub-id-type="publisher-manuscript">201309-1592OC</article-id><article-id pub-id-type="doi">10.1164/rccm.201309-1592OC</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group><subject>Interstitial Lung Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>C-X-C Motif Chemokine 13 (CXCL13) Is a Prognostic Biomarker of Idiopathic Pulmonary Fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vuga</surname><given-names>Louis J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Tedrow</surname><given-names>John R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pandit</surname><given-names>Kusum V.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tan</surname><given-names>Jiangning</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kass</surname><given-names>Daniel J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Jianmin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chandra</surname><given-names>Divay</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leader</surname><given-names>Joseph K.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gibson</surname><given-names>Kevin F.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaminski</surname><given-names>Naftali</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn2"><sup>‡</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sciurba</surname><given-names>Frank C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Duncan</surname><given-names>Steven R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Medicine and</aff><aff id="aff2"><label><sup>2</sup></label>Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania</aff></contrib-group><author-notes><fn id="fn1"><label>*</label><p>These authors contributed equally.</p></fn><fn id="fn2"><label><sup>‡</sup></label><p>Current address: Yale School of Medicine, New Haven, CT 06520.</p></fn><corresp>Correspondence and requests for reprints should be addressed to Steven R. Duncan, M.D., Pulmonary, Allergy, and Critical Care Medicine, 628 NW MUH, 3459 Fifth Avenue, Pittsburgh, PA 15213. E-mail: <email xlink:href="duncsr@upmc.edu">duncsr@upmc.edu</email></corresp></author-notes><pub-date pub-type="epub-ppub"><day>15</day><month>4</month><year>2014</year><pmc-comment>string-date: April 15, 2014</pmc-comment>
</pub-date><pmc-comment>Fake epub and ppub dates generated by PMC from publisher
pub-date/@pub-type='epub-ppub' </pmc-comment>
<pub-date pub-type="epub"><day>15</day><month>4</month><year>2014</year><pmc-comment>string-date: April 15, 2014</pmc-comment>
</pub-date><pub-date pub-type="ppub"><day>15</day><month>4</month><year>2014</year><pmc-comment>string-date: April 15, 2014</pmc-comment>
</pub-date><volume>189</volume><issue>8</issue><fpage>966</fpage><lpage>974</lpage><history><date date-type="received"><day>05</day><month>9</month><year>2013</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 by the American Thoracic Society</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri content-type="pdf" xlink:href="rccm.201309-1592OC.pdf"></self-uri><abstract><p><bold>Rationale:</bold> C-X-C motif chemokine 13 (CXCL13) mediates B-cell trafficking and is increased, proportionately to disease activity, in many antibody-mediated syndromes. Dysregulated B cells have recently been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis.</p><p><bold>Objectives:</bold> To determine if CXCL13 is associated with IPF progression.</p><p><bold>Methods:</bold> CXCL13 was measured in lungs by DNA microarray and immunohistochemistry, and in plasma by ELISA.</p><p><bold>Measurements and Main Results:</bold> CXCL13 mRNA was threefold and eightfold greater in IPF lungs (n = 92) compared with chronic obstructive pulmonary disease (COPD) (n = 191) and normal (n = 108) specimens, respectively (<italic>P</italic> < 0.0001). IPF lungs also showed increased CXCL13 staining. Plasma CXCL13 concentrations (pg/ml) were greater in 95 patients with IPF (94 ± 8) than in 128 subjects with COPD (53 ± 9) and 57 normal subjects (35 ± 3) (<italic>P</italic> < 0.0001). Circulating CXCL13 levels were highest in patients with IPF with pulmonary artery hypertension (<italic>P</italic> = 0.01) or acute exacerbations (<italic>P</italic> = 0.002). Six-month survival of patients with IPF in the highest quartile of plasma CXCL13 was 65 ± 10% versus 93 ± 10% in the others (hazard ratio, 5.5; 95% confidence interval, 1.8–16.9; <italic>P</italic> = 0.0008). CXCL13 increases by more than 50% in IPF serial assays, irrespective of initial values, also presaged respiratory failure (hazard ratio, 7.2; 95% confidence interval, 1.3–40.0; <italic>P</italic> = 0.008). In contrast, CXCL13 clinical associations in subjects with COPD were limited to modest correlations with FEV<sub>1</sub> (<italic>P</italic> = 0.05) and progression of radiographic emphysema (<italic>P</italic> = 0.05).</p><p><bold>Conclusions:</bold> CXCL13 is increased and is a prognostic biomarker in patients with IPF, and more so than in patients with COPD. This contrast indicates CXCL13 overexpressions are intrinsic to IPF, rather than an epiphenomenon of lung injury. The present data implicate CXCL13 and B cells in IPF pathogenesis, and support considerations for trials of specific B-cell–targeted therapies in patients with this intractable disease.</p></abstract><kwd-group><title>Keywords</title><kwd>adaptive immunity</kwd><kwd>autoimmunity</kwd><kwd>chronic obstructive pulmonary disease</kwd><kwd>CXCR5</kwd></kwd-group><counts><fig-count count="5"></fig-count><table-count count="3"></table-count><page-count count="9"></page-count></counts></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0008659 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0008659 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.38. |  |